AWM
LXRX icon

Apollon Wealth Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Apollon Wealth Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Buy
+11,378
New +$22.2K ﹤0.01% 1561

Other funds holding LXRX

PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
FGA
Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Apollon Wealth Management's LXRX Position: Q2 2026 in Review

Apollon Wealth Management opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 11,378 shares worth $27.3K. The stake represents ﹤0.01% of the portfolio and ranks #1561 among its holdings.

10 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Apollon Wealth Management held 11,378 shares of Lexicon Pharmaceuticals worth $27.3K as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Apollon Wealth Management position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1561 holding.
  • 10 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.